ProKidney's Upcoming Participation at a Major Virtual Conference
ProKidney Corp. (Nasdaq: PROK), based in Winston-Salem, is poised to make an impactful appearance at the upcoming H.C. Wainwright 4th Annual Kidney Virtual Conference. Known as a frontrunner in the field of clinical-stage cellular therapeutics, ProKidney is dedicated to addressing the challenges posed by chronic kidney disease (CKD). This conference represents an essential platform for discussing advancements in kidney treatments and facilitating investor engagement.
Conference Details You Should Know
The H.C. Wainwright conference is scheduled for a specific day featuring prominent topics related to kidney health. This virtual meeting will commence promptly at 1:30 PM ET, providing valuable insights through a fireside chat format. Attendees will benefit from an interactive environment designed to enhance dialogue with the management team of ProKidney.
Stream the Live Webcast
For those interested in participating in the conference, the live webcast will be available through the Investor Relations section of ProKidney’s official website. This allows both potential investors and stakeholders to tune in and gain insight into the company’s innovative approaches and future plans in kidney disease treatment.
About ProKidney Corp.
Established in 2015, ProKidney stands at the forefront of pioneering treatments for chronic kidney disease with its innovative cellular therapies. The company’s lead product, rilparencel, is at the center of ongoing Phase 2 and Phase 3 studies. This groundbreaking autologous cellular therapy aims to preserve kidney function especially for diabetic patients at a high risk of kidney failure. Rilparencel has earned recognition by receiving Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA. Such accolades underscore ProKidney's commitment to transformative healthcare solutions.
ProKidney’s advancements are the result of a decade of extensive research and dedication to improving patient outcomes. The focus on cellular therapy not only offers hope to patients but also signals a shift in the management of chronic kidney conditions.
Continuing the Conversation with Investors
Investors looking to engage in one-on-one meetings with company representatives are encouraged to reach out to their H.C. Wainwright representative. This interaction is vital for those interested in understanding the strategic direction of ProKidney and the potential impact of its innovative technologies in the healthcare landscape.
Frequently Asked Questions
What is ProKidney Corp. known for?
ProKidney Corp. specializes in cellular therapeutics aimed at treating chronic kidney disease, focusing on innovative treatments like rilparencel.
What event will ProKidney participate in?
ProKidney will participate in the H.C. Wainwright 4th Annual Kidney Virtual Conference, showcasing its strategies and developments in kidney treatment.
When will the conference take place?
The conference is scheduled to take place at 1:30 PM ET on a Monday in July, featuring a fireside chat format.
How can I access the live webcast?
The live webcast will be accessible through the Investor Relations section of ProKidney's website, providing an opportunity to learn about their advancements.
Who should I contact for investor inquiries?
Investors should reach out to Ethan Holdaway at ProKidney or Daniel Ferry from LifeSci Advisors for further inquiries and to arrange meetings.
